{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:25:06Z","timestamp":1788279906747,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eprac.2026.02.011","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:22:53Z","timestamp":1771460573000},"page":"1001-1007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review"],"prefix":"10.1016","volume":"32","author":[{"given":"Aoun","family":"Laurence","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti M.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9771-9120","authenticated-orcid":false,"given":"Eric S.","family":"Nylen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3675-9129","authenticated-orcid":false,"given":"Sabyasachi","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.eprac.2026.02.011_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl","key":"10.1016\/j.eprac.2026.02.011_bib2","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of Nonalcoholic Fatty Liver Disease","volume":"29","author":"Teng","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2026.02.011_bib3","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.ijo.0800571","article-title":"Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty","volume":"22","author":"Luyckx","year":"1998","journal-title":"Int J Obes"},{"key":"10.1016\/j.eprac.2026.02.011_bib4","article-title":"Differential effects of cardiometabolic risk factors on all-cause mortality in US adults with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","author":"Dukewich","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2026.02.011_bib5","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in Nonalcoholic Fatty Liver Disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.011_bib6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","article-title":"Fibrosis progression rate in biopsy-proven Nonalcoholic Fatty Liver Disease among people with diabetes versus people without diabetes: a multicenter study","volume":"165","author":"Huang","year":"2023","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.011_bib7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3350\/cmh.2024.0987","article-title":"Current Burden of Steatotic Liver Disease and fibrosis among adults in the United States, 2017-2023","volume":"31","author":"Kim","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.011_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","article-title":"Prospective evaluation of the prevalence of Non-Alcoholic Fatty Liver Disease and Steatohepatitis in a large middle-aged US cohort","volume":"75","author":"Harrison","year":"2021","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.eprac.2026.02.011_bib9","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.eprac.2026.02.011_bib10","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3350\/cmh.2023.0205","article-title":"Differences in liver and mortality outcomes of Non-Alcoholic Fatty Liver Disease by race and ethnicity: a longitudinal real-world study","volume":"29","author":"Nguyen","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"8","key":"10.1016\/j.eprac.2026.02.011_bib11","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2016.01.037","article-title":"Genetic factors that affect risk of Alcoholic and Nonalcoholic Fatty Liver Disease","volume":"150","author":"Anstee","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.eprac.2026.02.011_bib12","doi-asserted-by":"crossref","first-page":"e0728","DOI":"10.1097\/HC9.0000000000000728","article-title":"A comprehensive evaluation of candidate genetic polymorphisms in a large histologically characterized MASLD cohort using a novel framework","volume":"9","author":"Hakim","year":"2025","journal-title":"Hepatol Commun"},{"issue":"12","key":"10.1016\/j.eprac.2026.02.011_bib13","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.eprac.2026.02.011_bib14","doi-asserted-by":"crossref","first-page":"e16123","DOI":"10.1111\/liv.16123","article-title":"Global epidemiological impact of PNPLA3 I148M on liver disease","volume":"45","author":"Kozlitina","year":"2025","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.eprac.2026.02.011_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2026.02.011_bib16","first-page":"e70859","article-title":"Effectiveness of Resmetirom in reducing cholesterol levels in patients with Nonalcoholic Steatohepatitis: a systematic review and meta-analysis","volume":"16","author":"Bejitual","year":"2024","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.eprac.2026.02.011_bib17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.eprac.2026.02.011_bib18","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.eprac.2026.02.011_bib19","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0905633","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia","volume":"362","author":"Ladenson","year":"2010","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.eprac.2026.02.011_bib20","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of Semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2026.02.011_bib21","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2026.02.011_bib22","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.eprac.2026.02.011_bib23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b7 4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11-12","key":"10.1016\/j.eprac.2026.02.011_bib24","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.011_bib25","doi-asserted-by":"crossref","first-page":"e13037","DOI":"10.1002\/jgh3.13037","article-title":"Semaglutide improves metabolic dysfunction-associated steatohepatitis: a 10-year retrospective study","volume":"8","author":"Shah","year":"2024","journal-title":"JGH Open"},{"issue":"3","key":"10.1016\/j.eprac.2026.02.011_bib26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2026.02.011_bib27","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/biomedicines12051001","article-title":"Effects of once-weekly semaglutide on cardiovascular risk factors and metabolic dysfunction-associated steatotic liver disease in Japanese patients with type 2 diabetes: a retrospective longitudinal study based on real-world data","volume":"12","author":"Katsuyama","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.011_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/apt.18042","article-title":"Randomised clinical trial: design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures","volume":"60","author":"Vuppalanchi","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eprac.2026.02.011_bib29","article-title":"Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide","volume":"7","author":"Hartman","year":"2025","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.eprac.2026.02.011_bib30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2026.02.011_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2026.02.011_bib32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S2468-1253(23)00069-9","article-title":"Semaglutide in NASH-related cirrhosis: too late to the party?","volume":"8","author":"Bril","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2026.02.011_bib33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.12997\/jla.2023.12.3.213","article-title":"The cardiovascular effect of tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist","volume":"12","author":"Cho","year":"2023","journal-title":"J Lipid Atheroscler"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.011_bib34","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis","volume":"14","author":"Ong Lopez","year":"2024","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.011_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.16043","article-title":"The cellular and molecular mechanisms mediating the protective effects of sodium\u2013glucose linked transporter 2 inhibitors against metabolic dysfunction-associated fatty liver disease","volume":"27","author":"Ao","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.011_bib36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.eprac.2026.02.011_bib37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic Dysfunction\u2013Associated steatotic liver disease","volume":"393","author":"Targher","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2026.02.011_bib38","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2026.02.011_bib39","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2337\/dc23-1646","article-title":"Empagliflozin reduces liver fat in individuals with and without diabetes","volume":"47","author":"Abdelgani","year":"2024","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.011_bib40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2026.02.011_bib41","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.eprac.2026.02.011_bib42","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of Nonalcoholic Fatty Liver Disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.eprac.2026.02.011_bib43","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1136\/gutjnl-2024-332481","article-title":"Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease","volume":"73","author":"Mao","year":"2024","journal-title":"Gut"},{"issue":"42","key":"10.1016\/j.eprac.2026.02.011_bib44","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1074\/jbc.REV120.008387","article-title":"Sodium-glucose cotransporter-2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks","volume":"295","author":"Perry","year":"2020","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.011_bib45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose co-transporters and their inhibition: clinical physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab"},{"issue":"7","key":"10.1016\/j.eprac.2026.02.011_bib46","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2026.02.011_bib47","doi-asserted-by":"crossref","first-page":"E856","DOI":"10.1152\/ajpendo.00034.2025","article-title":"SGLT2 inhibitors use in kidney disease: what did we learn?","volume":"328","author":"Akunjee","year":"2025","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"10319","key":"10.1016\/j.eprac.2026.02.011_bib48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2026.02.011_bib49","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1038\/s41591-025-03759-8","article-title":"The people-first liver charter","volume":"31","author":"Lazarus","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.eprac.2026.02.011_bib50","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/liv.15880","article-title":"Disparities among ethnic groups in mortality and outcomes among adults with MASLD: a multicenter study","volume":"44","author":"Aboona","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.eprac.2026.02.011_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2025.100709","article-title":"A real-world experience with resmetirom: tolerability and access resmetirom: tolerability and access","volume":"4","author":"Shuaibi","year":"2025","journal-title":"Gastro Hep Adv"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.011_bib52","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2026.02.011_bib53","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/dci22-0044","article-title":"Structural racism as an upstream social determinant of diabetes outcomes: a scoping review","volume":"46","author":"Egede","year":"2023","journal-title":"Diabetes Care"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26007986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26007986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:27:26Z","timestamp":1781018846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26007986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1530891X26007986"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.02.011","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}